Growth hormone deficiency (GHD) is an endocrine disorder characterized by low or deficient secretion of growth hormone (GH) secondary to malfunction of the pituitary gland, a pea-sized structure located at the base of the brain that is responsible for the production of GH. The International Classification of Diseases (ICD-10) ICD-10-CM code for GHD is E23.0.
GHD in children can be classified as idiopathic or organic, which is further divided into congenital and acquired. GH is necessary for normal growth, as it fuels childhood growth and development. In an adults normal lifespan, GH is needed to maintain the amounts of body fat, muscle, and bone necessary for sustaining tissue and organ function. GHD acquired in adulthood is usually acquired through damage to the pituitary-hypothalamic region through trauma or tumors. This report does not cover childhood-onset GHD that progresses into adulthood.
Browse full report with TOC @ http://www.acutemarketreports.com/report/epicast-report-growth-hormone-deficiency-epidemiology-forecast-to-2024
In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 97,985 cases in 2014 to 100,494 cases in 2024, at an Annual Growth Rate (AGR) of 0.26%. GlobalData epidemiologists forecast a small increase in the AGR of the diagnosed prevalent cases of GHD from 2014-2024 for all included markets except for Germany and Japan. The majority of diagnosed prevalent cases of GHD in children in the 7MM are in boys. In the 7MM, 68.05% of the GHD cases in children are in boys and the trend is consistent in the individual markets. In adults, the distribution is also skewed towards men in the US and the 5EU.
GlobalData epidemiologists maintained consistent forecast methodology across all the 7MM, thus allowing for a meaningful comparison of the included parameters across the 7MM.
– The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the GHD diagnosed in children (=18 years) and in adults (>18 years) segmented by sex from 2014-2024. The forecast also provides GHD diagnosed cases in children segmented by the etiological classifications (idiopathic and organic; organic further segmented into congenital and acquired). The forecast for GHD diagnosed in adults are further segmented by etiological classifications (idiopathic and acquired).
– The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
View all reports of this category @ http://www.acutemarketreports.com/category/petrochemicals-market
Reasons to buy
– Develop business strategies by understanding the trends shaping and driving the global GHD market.
– Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.
– Identify the percentage of GHD diagnosed prevalent cases by etiological classification.
For More Information Click Here – Acute Market Reports
About Acute Market Reports
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. Acute Market Reports provide online reports from over 100 best publishers and upgrade Acute Market Reports collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Acute Market Reports database consists of 200,000+ market research reports with detailed & minute market research.
Office No 01, 1st Floor,
Aditi Mall, Baner, Pune,
MH, 411045 India
Phone (India): +91 7755981103
Toll Free (US/Canada): +1-855-455-8662